Focus on Anticoagulation Care

Back to articles

Generic Substitution of Warfarin: The Debate Continues

KEY POINT

As the debate continues about the substitution of Coumadin (DuPont) with Barr Laboratories’ warfarin sodium in patients in need of oral anticoagulation, new data indicate that the two products could be substituted without increasing monitoring costs or the incidence of adverse reactions in a managed care organization.

SOURCES

Swenson CN, Fundak G. Observational cohort study of switching warfarin sodium products in a managed care organization. Am J Health-Syst Pharm. 2000;57:452–5.

Data on file. Barr Laboratories, Inc., Pomona, NY. 1997 Aug.

Neutal JM, Smith DHG. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovasc Rev Rep. 1998;19:49–52,55–9.

Handlen J et al. A blinded randomized, crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin. Prevent Cardiol. 1998;4:13–20.

DeMonaco HJ, Irby BT. Warfarin sodium: "curiouser and curiouser!" MGH [Massachusetts General Hospital] Drug Ther. 1997;7(8):1–3.